Need Help? Call : (310) 914-5007
Need Help? Call : (310) 914-5007
The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
What Is The Investigation About?
On May 6, 2025, Myriad released its first quarter 2025 financial results, revealing “revenue of $196 million declined by 3% year-over-year” and “pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.” Additionally, the Company announced reduced financial guidance for 2025 “reflecting first quarter 2025 results and the current business outlook.”
On this news, Myriad’s stock price fell $3.00, or 41.3%, to close at $4.27 per share on May 7, 2025, thereby injuring investors.
If you suffered a loss on your Myriad Genetics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.
© 2025 The Law Offices of Frank R. Cruz. A Professional Services Corporation.
Website Designed & Developed By ITIFFY Consultants.